Freemont Management S.A. Biomarin Pharmaceutical Inc Transaction History

Freemont Management S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$74.43 - $92.22 $3.15 Million - $3.9 Million	-42,300 Reduced 83.1%	8,600 $708,000
Q1 2024 May 13, 2024	SELL	$83.81 - $99.0 $1.32 Million - $1.56 Million	-15,800 Reduced 23.69%	50,900 $4.45 Million
Q3 2023 Nov 09, 2023	SELL	$85.07 - $94.48 $961,290 - $1.07 Million	-11,300 Reduced 14.49%	66,700 $5.9 Million
Q2 2023 Aug 08, 2023	BUY	$86.68 - $100.3 $6.76 Million - $7.82 Million	78,000 New	78,000 $6.76 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Freemont Management S.A., based on Form 13F filings with the SEC.

Stay updated on Freemont Management S.A. with notifications on news.